If you lose a child, you lose a generation. No child should die from malaria. But almost 600,000 people died from the disease in 2023, according to the World Health Organization World Malaria Report 2024, which was published today. And most of these deaths were young children in Africa. However, there is hope. Let’s come together to finally defeat malaria. It’s our responsibility. Watch our full film series here: https://lnkd.in/gS9xvAeC Michael Adekunle Charles | Nekoye Otsyula | Abdisalan M. Noor | Bernhards Ogutu
Info
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
Externer Link zu Novartis
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Basel, Baselstadt
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand und Gene and cell therapy
Orte
Beschäftigte von Novartis
-
Guy Dickinson
Figuring out #FutureOfWork: GenerativeAi + Employee Experience + Behavioural Design + Capability Building + Digital Skills
-
David Yee
Head Portfolio Systems, Portfolio Strategy & Analytics, Strategy & Growth at Novartis
-
Rodolfo Garcia de Alba Cassaigne
Regional Category Procurement Director, US Marketing Agencies
-
Kelley Dallas Priddy, M.S.
Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning
Updates
-
A Multiple Sclerosis (MS) diagnosis can feel difficult to navigate. Five women living with MS tell their story, sharing the importance of understanding their diagnosis and finding their voice in conversations with their care team. Watch Ellen, Trish, Elisabeth, Louisa, and Christina’s stories to learn how they managed their MS journey after their diagnosis. Together, we can advocate for early and accurate diagnosis for everyone living with MS. To learn more about decision making with MS, go to https://lnkd.in/g2RPFMjp
-
Throughout the year our people give and volunteer to partner organizations across 63 causes and beneficiary areas on company time. To say thanks, Novartis is rewarding generosity with generosity. For the first time, we are matching x5 any donations given by Novartis employees under our Gift of a Gift seasonal employee giving campaign so we can have an even bigger impact on society’s biggest challenges and unmet needs this giving season. #InternationalVolunteerDay https://lnkd.in/gd8SegUu
-
“Disability and inclusion are important because we know diversity of thought is how we come with innovative ideas, and innovative ideas is how you transform an industry or a sector”. Meet Brian Robbins, our Head Integrated Insights Oncology International. A strong supporter of our Disability-Equity commitments, he is motivated by his personal experiences and hearing loss as a result of a cold, Brian believes inclusion is critical in reaching collective impact, so that we can reimagine medicine, together. Today we’re marking International Day of Persons with Disabilities. Take a few minutes to listen to Brian’s story and reflect on the daily impact that invisible disabilities can have. Learn more about Disability-Equity at Novartis: https://lnkd.in/gwykXNND #PositivelyPurple #ThriveTogether #NovartisTogether
-
Today, Novartis upgraded our mid-term guidance at our Meet Novartis Management event for investors and analysts in London. As our leadership team outlined, Novartis projects higher sales growth over the next five years. These updated expectations are a result of our robust clinical development program, since transforming into an innovative medicines company. As a result, Novartis now has more than 30 potential high-value medicines in our current pipeline. This revised outlook also builds on the strong momentum outlined in recent quarterly earnings as our current portfolio of breakthrough treatments continues to reach more patients in new markets. We’re excited about the road ahead. And look forward to seeing how these medicines improve and extend patients’ lives in the years to come. You can learn about our updated guidance at https://lnkd.in/eBBf7ZeR #reimaginingmedicine
-
-
Innovation only matters when it reaches those who need it. Today, we are honored that Novartis has been ranked first in the 2024 Access to Medicine Index. This recognition reinforces our commitment to improving access to breakthrough medicines for people around the world, regardless of their location or socio-economic status. While we are grateful for this recognition, there is still a large unmet need for medicines —some life-changing, others potentially life-saving— and Novartis is committed to further broaden access to innovation and create sustainable impact. Thank you to our 70,000+ associates and our partners who work tirelessly to make inclusive healthcare a reality. Because every patient matters. Everywhere. #AccessToMedicine #Sustainability #HealthEquity Access to Medicine Foundation
-
-
Novartis is on a mission to break down barriers to cardiovascular, renal, and metabolic (CRM) treatments through empathy, access, and innovation. In a recent interview, Dianne Auclair Rocha, SVP and TA Head, Cardiovascular, Renal and Metabolic in the US and Vasilisa Sazonov, Therapy Area Head Cardiovascular, Renal, Metabolic internationally talked about their focus on prevention through education, early screening efforts, and partnerships to reduce access barriers for patients. The leaders emphasized the importance of understanding patient needs and fostering a patient-centered approach, as well as the role of personalized medicine and digital health in the future. Hear more about these leaders' perspectives on the importance of tackling the challenges in the cardiovascular, renal and metabolic space in the article: https://lnkd.in/gTaQHTEJ
Live. Magazine
live.novartis.com
-
We’re thrilled to announce that Novartis, a proudly Swiss company, is an Official Partner of the Eurovision Song Contest 2025, hosted in our headquarters city of #Basel, #Switzerland. Like Novartis, the Eurovision Song Contest was founded in Switzerland, and we’re delighted to offer our support to this legendary contest and our home country. For ten unforgettable days, Basel will transform into a global hub of creativity and community, bringing together millions of viewers from across the world and thousands of visitors to Basel. With 78,000 employees from over 100 countries, at Novartis, we believe in the power of collective creativity and international collaboration — values we share with Eurovision. So, here’s to seizing the moment and meeting at the intersection of science and creativity! Stay tuned for more news on our involvement. Novartis, where health takes center stage. #EurovisionBasel #novartislife #HealthCentreStage #ESC2025 #Eurovision #Eurovision2025 European Broadcasting Union (EBU) SRG SSR
-
-
This FDA approval for adults with newly diagnosed chronic myeloid leukemia (#CML) is vital for the clinical and patient communities. As a part of our 20+-year commitment to innovation and support in CML, we continue to work alongside the clinical and patient communities. #ReimaginingMedicine
We are proud to announce the FDA approval for adults with newly diagnosed Ph+ chronic myeloid leukemia (#CML) in chronic phase. About 10,000 people each year are diagnosed with chronic myeloid leukemia in the US. With this approval, up to 4 times the number of currently eligible patients will have the opportunity to explore a new treatment. #NovartisNews #ReimaginingMedicine
Verbundene Seiten
Ähnliche Seiten
Aktien
NVS
NYSE
Verzögerung von 20 Minuten
97,11 $
0,34 (0,351 %)
- Aktiv
- 96,16
- Niedrig
- 96,062
- Hoch
- 97,59
Daten von Refinitiv
Mehr Informationen aufFinanzierung
Novartis
Insgesamt 2 Finanzierungsrunden
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
2.487.694.394,00 $